|Bid||0.0000 x 800|
|Ask||0.0000 x 800|
|Day's range||2.0700 - 2.2000|
|52-week range||1.3300 - 4.6800|
|Beta (5Y monthly)||2.03|
|PE ratio (TTM)||99.09|
|Earnings date||13 Aug 2020 - 17 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||7.00|
Since the coronavirus outbreak, robots have filled up several job vacancies caused by social distancing orders. Here are five robotics and related stocks investors should closely watch.
Accuray (ARAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Accuray (ARAY) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Welcome to Accuray's conference call to review financial results for the third quarter of fiscal year 2020, which ended March 31, 2020. Joining us today are Josh Levine, Accuray's President and Chief Executive Officer; and Shig Hamamatsu, Accuray's Senior Vice President and Chief Financial Officer.
Accuray (ARAY) delivered earnings and revenue surprises of 200.00% and 3.21%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
DaVita (DVA) continues to gain traction from strong international foothold, strategic buyout of dialysis centers and DaVita Kidney Care.
HealthEquity's (HQY) fiscal fourth-quarter earnings benefit from higher revenues and solid performing Service, Custodial and Interchange segments.
Allscripts (MDRX) fourth-quarter results gain from higher revenues along with growth in bookings. Contraction in both gross and operating margins remains a woe.